Clinical trials: Empagliflozin
Diabetes Type 1
A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes
The goal of this clinical trial is to learn if Empagliflozin and Semaglutide, individually and combined, added to Automated Insulin Delivery (AID) works to improve time-in-range in adults living with Type 1 Diabetes.
- Trial name
- SEMPA (NCT06894784)
- Testing
- Intervention Period 1: Semaglutide + Empagliflozin
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Lupus Nephritis (LN)
The Efficacy of Empagliflozin on Kidney Functions in Lupus Nephritis Population
Systemic lupus erythematosis (SLE) is a chronic, most probably auto-immune multisystem disease marked by relapsing-remitting course and the formation of a range of autoantibodies.
- Trial name
- NCT07700940
- Testing
- Empagliflozin (25 Mg Tab) along with standard medical therapy
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Ahmed Yehia Ismail
Diabetes Mellitus, Type 1
Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)
The study will investigate the efficacy, safety, tolerability and Pharmacokinetic(PK) of 3 doses of empagliflozin compared with placebo over 26 weeks in 960 patients with type 1 diabetes mellitus as adjunctive therapy to insulin
- Trial name
- NCT02580591
- Testing
- Empagliflozin
- Where
- 189 sites in United States, Australia and 22 more
- Volunteers
- 977 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2, Heart Failure
A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record
The aim of this clinical trial is investigate the comparative effectiveness of empagliflozin and dapagliflozin for the treatment of diabetes, chronic kidney disease, and heart failure.
- Conditions
- Diabetes Mellitus, Type 2, Heart Failure, Chronic Kidney Diseases
- Trial name
- APPLE TREE (NCT06642272)
- Testing
- Empagliflozin 10 MG, Dapagliflozin 10 MG
- Where
- 12 sites in Denmark
- Volunteers
- 17,200 people
- Sponsor
- Herlev and Gentofte Hospital
Healthy
Investigation of the Effect of Food on the Bioavailability of a 25 mg Empagliflozin Tablet as Well as Assessment of Dose Proportionality Between 10 mg and 25 mg Empagliflozin Tablets Under Fasting Conditions.
Investigation of food effect on the bioavailability of a 25 mg empagliflozin tablet and assessment of dose proportionality between 10 mg and 25 mg empagliflozin tablets under fasting conditions.
- Trial name
- NCT01451775
- Testing
- Empagliflozin
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Heart Failure With Preserved Ejection Fraction (HFPEF)
This Will be a Randomized Comparison of the Proteomic Effects of Vicadrostat/Empagliflozin Versus Empagliflozin and Versus Empagliflozin/Spironolactone in Heart Failure Patients With Preserved Ejection Fraction
The SPECTRA-HFpEF Study is a randomized, double-blind, Phase 2 clinical study designed to evaluate and compare the biological effects of vicadrostat in combination with empagliflozin, empagliflozin alone, and spironolactone in…
- Trial name
- SPECTRA-HFpEF (NCT07857772)
- Testing
- empa plus vica, Comparator: empa 10 plus spironolactone
- Volunteers
- 200 people
- Sponsor
- Baim Institute for Clinical Research
Overweight Subject, Healthy Subjects
A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin
The purpose of this study is to characterize the drug-drug intereaction of HDM1002 and metformin, empagliflozin, midazolam, valsartan, and warfarin in overweight/obese adult subjects.
- Trial name
- NCT07331389
- Testing
- Metformin, Empagliflozin, Midazolam
- Where
- China
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Covid19
Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE
This is a randomized, open label, adaptive platform trial to compare the effectiveness of antithrombotic and additional strategies for prevention of adverse outcomes in COVID-19 positive inpatients
- Trial name
- ACTIV-4A (NCT04505774)
- Testing
- theraputic heparin, prophylactic heparin, P2Y12
- Where
- 101 sites in United States, Brazil and 2 more
- Volunteers
- 3,591 people
- Sponsor
- Matthew Neal MD
Acute Decompensated Heart Failure
Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure
Heart failure is the most common hospital admission diagnosis and shows increasing incidence and prevalence in Germany, the United States and worldwide. Improvements in the primary treatment conditions for e.g.
- Trial name
- EMPAG-HF (NCT04049045)
- Testing
- Empagliflozin 25 mg
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Christian Schulze
Gestational Diabetes
Empagliflozin and the Preservation of Beta-cell Function in Women with Recent Gestational Diabetes
Double-blind, parallel arm, randomized controlled trial, in which non-lactating women with recent GDM who are between 6 to 36 months postpartum to be randomized to either empagliflozin 10 mg daily or matching placebo.
- Trial name
- EMPA post-GDM (NCT03215069)
- Testing
- Empagliflozin 10 MG
- Where
- Canada
- Volunteers
- 91 people
- Sponsor
- Mount Sinai Hospital, Canada
Tricuspid Regurgitation, Right Ventricular Dilatation
Pharmacological Reduction of Right Ventricular Enlargement
Functional tricuspid regurgitation (TR) has been regarded as a secondary phenomenon of heart failure (HF), mitral valve (MV) disease or atrial fibrillation.
- Trial name
- PROVE (NCT04345796)
- Testing
- Carvedilol+Empagliflozin, Carvedilol, Empagliflozin
- Where
- 3 sites in South Korea
- Volunteers
- 56 people
- Sponsor
- Asan Medical Center
Diabetes Mellitus, Pharmacokinetics
The Effect of Morning Versus Evening Administration on The Pharmacokinetics and Pharmacodynamics of Empagliflozin
An Open-label, One way, Two period Comparative study To Determine The effect of Morning Versus Evening administration of Empagliflozin 10mg on Its Pharmacokinetics And Pharmacodynamics in Healthy Adults
- Conditions
- Diabetes Mellitus, Pharmacokinetics, Pharmacodynamics
- Trial name
- NCT03895229
- Testing
- Empagliflozin 10 MG Oral Tablet [Jardiance]
- Where
- Egypt
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Type 2 Diabetes Mellitus (T2DM)
Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg
An Open Label, Balanced, Randomized, Single dose, Two treatment, Two sequence, Two period, two way crossover, Oral Bioequivalence Study of test product of Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet and…
- Trial name
- NCT07266766
- Testing
- Empagliflozin / Metformin HCl XR Tablets, Synjardy® XR (empagliflozin and metformin hydrochloride extended-release Tablets)
- Where
- India
- Volunteers
- 40 people
- Sponsor
- Humanis Saglık Anonim Sirketi
Type 2 Diabetes, High Blood Pressure
Polypill for Prevention of Cardiomyopathy
This study will investigate the utility of a polypill-based strategy for patients with type 2 diabetes mellitus and high risk of heart failure (HF), as assessed via the WATCH-DM risk score.
- Trial name
- PolyPreventHF (NCT06143566)
- Testing
- Polypill, Combined prescription of the individual medications
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Texas Southwestern Medical Center
Diabete Mellitus
The Efficacy and Safety of Empagliflozin - Linagliptin and Empagliflozin- Metformin Therapy in Reduction of Body Weight in Type 2 Diabetic Patients .
The goal of this clinical trial is - Comparison of Empagliflozin - Linagliptin with Empagliflozin - Metformin combination therapy in reduction of body weight in T2DM Patients and it included 200 diabetic subjects with total study…
- Trial name
- NCT07247656
- Testing
- (Empagliflozin 10 mg+ Tab Linagliptin 5mg), Tab Empagliflozin 10 mg + Tab Metformin 500 mg
- Where
- Pakistan
- Volunteers
- 200 people
- Sponsor
- Bahria University
Diabetes Mellitus, Type 2
The Effect Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes
The purpose of this study is to investigate the effect of empagliflozin on oxidative stress in patients with type 2 diabetes. The association is examined by comparing the difference in oxidative modifications before and after 14…
- Trial name
- EMPOX (NCT02890745)
- Testing
- Empagliflozin
- Where
- Denmark
- Volunteers
- 31 people
- Sponsor
- Henrik Enghusen Poulsen
Diabetes Mellitus, Type 2, Sarcopenia
Mediterranean Diet, Circuit Resistance Training, Empagliflozin in Elderly With Type 2 Diabetes: a Study Protocol
Primary objective: To assess the effects of a modified plant-based Mediterranean diet (vegeterranean diet), circuit resistance training (CRT) and empagliflozin alone or in combination on metabolic and physical function in elderly…
- Conditions
- Diabetes Mellitus, Type 2, Sarcopenia, Weight Loss
- Trial name
- NCT03560375
- Testing
- Circuit resistance training (CRT), Vegeterranean diet (V-Med diet), Empagliflozin 10 MG
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Albuminuria
Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin
Sickle cell anemia (SCA) is an inherited red blood disorder. The kidneys are among the most commonly affected organ systems in SCA.
- Trial name
- EMPA-CKD (NCT07175051)
- Testing
- Empagliflozin (oral)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Illinois Chicago
Diabetes Mellitus, Type 2, Coronary Artery Disease
SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI)
Patients with type 2 diabetes mellitus (DM) have higher risk of major cardiovascular events (MACE) and renal disfunction. The Sodium-glucose cotransporter-2 inhibitors (iSGLT2) reduces hyperglycemia in patients with type 2 DM and…
- Conditions
- Diabetes Mellitus, Type 2, Coronary Artery Disease, Acute Kidney Injury
- Trial name
- SAFE-PCI (NCT05037695)
- Testing
- empagliflozin 25 MG
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- University of Sao Paulo General Hospital
Heart Failure With Preserved Ejection Fraction, End Stage Renal Disease on Dialysis
EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease
The presence of CKD has been linked to the development of HFpEF. Currently, the treatment for HFpEF is limited. SGLT2i are one of the few drug classes that have proven efficacy in HFpEF in randomized controlled trials.
- Trial name
- EMPA-PRED (NCT06249945)
- Testing
- Empagliflozin 25 MG
- Where
- 2 sites in Taiwan
- Volunteers
- 150 people
- Sponsor
- National Taiwan University Hospital